|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and Disability-adjusted
life-years for 32 cancer groups, 1990 to 2015 a systematic analysis
for the global burden of disease study. JAMA Oncol. 3:524–548.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iwata H: Future treatment strategies for
metastatic breast cancer: Curable or incurable? Breast Cancer.
19:200–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanda M, Tanaka C, Kobayashi D, Tanaka H,
Shimizu D, Shibata M, Takami H, Hayashi M, Iwata N, Niwa Y, et al:
Epigenetic suppression of the immunoregulator MZB1 is associated
with the malignant phenotype of gastric cancer. Int J Cancer.
139:2290–2298. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herold T, Mulaw MA, Jurinovic V, Seiler T,
Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K,
Mansmann U, et al: High expression of MZB1 predicts adverse
prognosis in chronic lymphocytic leukemia, follicular lymphoma and
diffuse large B-cell lymphoma and is associated with a unique gene
expression signature. Leuk Lymphoma. 54:1652–1657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsumura S, Imoto I, Kozaki K, Matsui T,
Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S and Inazawa J:
Integrative array-based approach identifies MZB1 as a frequently
methylated putative tumor suppressor in hepatocellular carcinoma.
Clin Cancer Res. 18:3541–3551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenbaum M, Andreani V, Kapoor T, Herp S,
Flach H, Duchniewicz M and Grosschedl R: MZB1 is a GRP94
cochaperone that enables proper immunoglobulin heavy chain
biosynthesis upon ER stress. Genes Dev. 28:1165–1178. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cox JS, Shamu CE and Walter P:
Transcriptional induction of genes encoding endoplasmic reticulum
resident proteins requires a transmembrane protein kinase. Cell.
73:1197–1206. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hochachka PW, Buck LT, Doll CJ and Land
SC: Unifying theory of hypoxia tolerance: Molecular/metabolic
defense and rescue mechanisms for surviving oxygen lack. Proc Natl
Acad Sci USA. 93:9493–9498. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koumenis C: ER stress, hypoxia tolerance
and tumor progression. Curr Mol Med. 6:55–69. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fernandez PM, Tabbara SO, Jacobs LK,
Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA and Patierno SR:
Overexpression of the glucose-regulated stress gene GRP78 in
malignant but not benign human breast lesions. Breast Cancer Res
Treat. 59:15–26. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fujimoto T, Onda M, Nagai H, Nagahata T,
Ogawa K and Emi M: Upregulation and overexpression of human X-box
binding protein 1 (hXBP-1) gene in primary breast cancers. Breast
Cancer. 10:301–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shibata M, Kanda M, Tanaka H, Umeda S,
Miwa T, Shimizu D, Hayashi M, Inaishi T, Miyajima N, Adachi Y, et
al: Overexpression of Derlin 3 is associated with malignant
phenotype of breast cancer cells. Oncol Rep. 38:1760–1766. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shibata M, Kanda M, Shimizu D, Tanaka H,
Umeda S, Hayashi M, Inaishi T, Miyajima N, Adachi Y, Takano Y, et
al: Expression of regulatory factor X1 can predict the prognosis of
breast cancer. Oncol Lett. 13:4334–4340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cserni G, Chmielik E, Cserni B and Tot T:
The new TNM-based staging of breast cancer. Virchows Archi.
472:697–703. 2018. View Article : Google Scholar
|
|
15
|
Shibata M, Kanda M, Shimizu D, Tanaka H,
Umeda S, Miwa T, Hayashi M, Inaishi T, Miyajima N, Adachi Y, et al:
RASEF expression correlates with hormone receptor status in breast
cancer. Oncol Lett. 16:7223–7230. 2018.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Finn RS, Dering J, Conklin D, Kalous O,
Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Subik K, Lee JF, Baxter L, Strzepek T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and
Tang P: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67
and AR by immunohistochemical analysis in breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
|
|
19
|
McGrath EP, Logue SE, Mnich K, Deegan S,
Jäger R, Gorman AM and Samali A: The unfolded protein response in
breast cancer. Cancers (Basel). 10:3442018. View Article : Google Scholar
|
|
20
|
Ansa-Addo EA, Thaxton J, Hong F, Wu BX,
Zhang Y, Fugle CW, Metelli A, Riesenberg B, Williams K, Gewirth DT,
et al: Clients and oncogenic roles of molecular chaperone
gp96/grp94. Curr Top Med Chem. 16:2765–2778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Belkaya S, Murray SE, Eitson JL, de la
Morena MT, Forman JA and van Oers NS: Transgenic expression of
microRNA-185 causes a developmental arrest of T cells by targeting
multiple genes including Mzb1. J Biol Chem. 288:30752–30762. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Flach H, Rosenbaum M, Duchniewicz M, Kim
S, Zhang SL, Cahalan MD, Mittler G and Grosschedl R: Mzb1 protein
regulates calcium homeostasis, antibody secretion, and integrin
activation in innate-like B cells. Immunity. 33:723–735. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rajapaksa G, Thomas C and Gustafsson JÅ:
Estrogen signaling and unfolded protein response in breast cancer.
J Steroid Biochem Mol Biol. 163:45–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Andruska N, Zheng X, Yang X, Helferich WG
and Shapiro DJ: Anticipatory estrogen activation of the unfolded
protein response is linked to cell proliferation and poor survival
in estrogen receptor α-positive breast cancer. Oncogene.
34:3760–3769. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Friedland JC, Smith DL, Sang J, Acquaviva
J, He S, Zhang C and Proia DA: Targeted inhibition of Hsp90 by
ganetespib is effective across a broad spectrum of breast cancer
subtypes. Invest New Drugs. 32:14–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jhaveri K, Wang R, Teplinsky E,
Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S,
Patil S, et al: A phase I trial of ganetespib in combination with
paclitaxel and trastuzumab in patients with human epidermal growth
factor receptor-2 (HER2)-positive metastatic breast cancer. Breast
Cancer Res. 19:892017. View Article : Google Scholar : PubMed/NCBI
|
